Class

Class III antiarrhythmic
Beta-blocker


Pharmacodynamics
  • Class III antiarrhythmic drug with both class II beta-adrenergic-receptor blocking (class II) and AP prolonging (class III) actions
  • Racemic mixture of D- and L-sotalol
  • L-isomer contains all of beta-adrenergic-blocking activity
  • D- and L-isomers share AP prolonging effects

Pharmacokinetics
  • Simple pharmacokinetics, therefore has few direct drug interactions
  • Well absorbed orally, bioavailability 100%
  • Low lipid solubility
  • Not metabolised by liver
  • Not plasma protein bound
  • Half-life 12 hours
  • Renal excretion of predominately unchanged form

Clinical uses
  • Ventricular arrhythmias
  • Maintenance of sinus rhythm in patients with AF
  • Decreases threshold for cardiac defibrillation

Adverse effects
  • Prolongs QT:
    • Dose-related incidence of TdP (6% at highest recommended daily dose)
  • Reduction in LV function in patients with heart failure
  • Acute asthma

References
  • Katzung BG. Basic & Clinical Pharmacology. 14th ed. United States of America: McGraw-Hill Education; 2018. 239-244 p.

Pharm 101 700

Pharmacology 101

Top 200 drugs

MBBS (UWA) CCPU (RCE, Biliary, DVT, E-FAST, AAA) Emergency Medicine Advanced Trainee in Melbourne, Australia. Special interests in diagnostic and procedural ultrasound, medical education, and ECG interpretation. Editor-in-chief of the LITFL ECG Library. Twitter: @rob_buttner

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.